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Abstract 
Myeloid zinc finger 1 (MZF1) belongs to the SCAN-Zinc Finger (SCAN-ZF) transcription 
factor family that has recently been implicated in a number of types of cancer. Although 
the initial studies concentrated on the role of MZF1 in myeloid differentiation and 
leukemia, the factor now appears to be involved in the etiology of major solid tumors such 
as lung, cervical, breast and colorectal cancer. Here we discuss the regulation of MZF1 
that mediated its recruitment and activation in cancer, concentrating on posttranslational 
modification by phosphorylation and sumoylation, interaction with promyelocytic 
leukemia nuclear bodies and its association with co-activators and co-repressors.   
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(1) Introduction- MZF1 in cancer 
 
Myeloid zinc finger 1 (MZF1 aka MZF1A, MZF1B, ZSCAN6, ZNF42 and ZFP98) is a SCAN-
Zinc Finger (SCAN-ZF) transcription factor family member and has been implicated in a 
number of cancers and cellular malignancies (Hromas, Morris et al. 1995, Gaboli, Kotsi et 
al. 2001, Reymann and Borlak 2008, Mudduluru, Vajkoczy et al. 2010, Rafn, Nielsen et al. 
2012, Deng, Wang et al. 2013). We will refer here to the human gene or protein as MZF1 
(Fig 2). Zinc finger proteins have in common the possession of small structural motifs, 
often occurring in clusters that can coordinate divalent cations such as Zn++, forming 
finger-like structures that can bind to, most notably the major groove in DNA and 
permitting sequence-specific binding. MZF1 was first suspected to be involved in 
malignancy in studies on hematopoietic development along the myeloid lineage. MZF1 
appeared to function as a gene repressor in this context, repressing the CD34 or c-myb 
promoter activity essential for hematopoietic differentiation (Perrotti, Melotti et al. 1995). 
Such a block towards differentiation suggested the emergence of a leukemic phenotype 
(Perrotti, Melotti et al. 1995). Neoplastic cell transformation by MZF1 was indeed 
demonstrated using the NIH3T3 transformation model, and forced expression of MZF1 
led to emergence of cells that grew rapidly in vivo and initiated tumors in athymic mice 
(Hromas, Davis et al. 1996). Subsequent studies showed that immortalized myeloid cells 
were protected from IL-3 withdrawal-mediated apoptosis by MZF1(Hromas 1996). MZF1 
activity again resulted in cells that formed tumors in congenic mice. However, there was 
some ambivalence in the role ascribed to MZF1 in hematopoietic cancers. Gaboli et al 
showed that mzf1-/- mice underwent a large increase in autonomous proliferation of 
hemopoietic progenitors and suggested that the mzf1 gene might function as a suppressor 
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of blood cell cancers(Gaboli, Kotsi et al. 2001). The reasons for discrepancies were not 
obvious although they could be connected to the findings that the mzf1 gene can give rise 
to at least two transcripts that may have contrasting properties in the cell (see below).  
The development of other types of solid tumor cancers have subsequently been 
associated with MZF1. Analysis of data from the TCGA website indicated significant 
amplification of the MZF1 gene in human breast, uterine, lung and bladder cancers as well 
as increased levels of mutation in colorectal cancer (Fig.1). By contrast, in Glioma, a 
significant number of cancers showed MZF1 deletion (Fig. 1). In addition, analysis of 
mRNA levels in a series of human cancers indicated large increases in MZF1 mRNA in 
myeloma and cutaneous melanoma compared to normal tissues (Oncomine: 
https://www.oncomine.org)  
Likewise MZF1 appeared to play roles in multiple cancers as indicated by studies in 
cellular and animal models. In experiments in SK-Hep1 HCC tissue culture cells in vitro, 
inhibition of MZF1 expression using antisense technology led to reduced growth in 
hepatocellular carcinoma(Hsieh, Wu et al. 2007). This finding might not have been 
predicted from study of human liver tumors in which evidence of MZF1 amplification or 
mutation was low (Fig. 1). In addition, MZF1 was shown to mediate migration, invasion 
and in vivo metastasis in colorectal cancer models in vitro (RKO and SW480 cells) and 
cervical cancer cells (Mudduluru, Vajkoczy et al. 2010). In these studies the gene for the 
receptor tyrosine kinase AXL was shown to be activated by MZF1 at the transcriptional 
level, and knockdown of MZF1 by RNA interference reduced migration and invasion. AXL 
activity has been associated with a metastatic phenotype (Asiedu, Beauchamp-Perez et al. 
2014). Moreover, MZF1 and AXL levels were positively correlated and significantly higher 
in resected colorectal tumors compared to normal tissues(Mudduluru, Vajkoczy et al. 
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2010). In three-dimensional breast cancer model derived from primary human breast 
cancer, MZF1 was found to bind to the enhancer element and drive the expression of the 
cathepsin B(CTSB) gene, a key molecule required for tumor invasion (Rafn, Nielsen et al. 
2012) Rafn et al were able to define a signaling cascade that was initiated by ERBB2 
activation through transforming growth factor receptor RII (TGFRII) binding and 
propagated by the kinases, CDC42BP, ERK2, PAK4 and PKCA.  This study gave the first 
convincing indication of an activating signaling pathway that might be located upstream 
of human MZF1 in cancer signaling (see below). A role for the TGFRII ligand, TGF-1 in 
MZF1 function was likewise indicated by studies showing that TGF- released by 
MDA_MB-231mammary cancer cells could cause mesenchymal stem cells to differentiate 
into cancer associated fibroblasts (CAF) in a process dependent on MZF1(Weber, Kothari 
et al. 2014). TGF factors classically regulate transcription through a series of Smad factors 
that can translocate to the nucleus and modulate gene expression(Derynck and Zhang 
2003).TGF-1 can play paradoxical roles in cancer, in some contexts inhibiting tumor 
growth although in others triggering cell invasion and local immune suppression 
(Massague 2008). Effects on CAF may play a significant role in such TGF-1 functions. In 
lung adenocarcinoma another mechanism for MZF1 activation has been described (Tsai, 
Wu et al. 2014). MZF1 activity was triggered by the loss of Liver Kinase B1 (LKB1) leading 
to elevated levels of MYC, increased migration and invasion of CL-1 lung adenocarcinoma 
cells. Loss of LKB1 was shown to be associated with inactivation of the tumor suppressor 
TP53 and enhanced expression of the lung proto-oncogene protein NK2 homeobox 1 
(NKX2-1) (Tsai, Wu et al. 2014). MZF1 was also reported to be activated downstream of 
NKX2 in human papillovirus driven cancer. MZF1 led to upregulation of FOXM1 
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expression, again promoting migration, invasion and stemness that may be related to 
increase in Wnt /  catenin signaling (Chen, Cheng et al. 2014). Another cancer relevant 
transcriptional target of MZF1 may be the protooncogene CDC37, which is required for 
oncogenic kinase maintenance and plays a role in the emergence of prostate 
carcinoma(Huang, Grammatikakis et al. 1998, Gray, Prince et al. 2008). Overexpression of 
CDC37 drives proliferation, survival and AR activity in prostate cancer, and thus induction 
of CDC37Cdc37 by MZF1 may have a critical role in development of prostate 
cancer(Calderwood 2015).  
A recurrent theme in a number of the studies is a role for MYC in association with MZF1, 
and MYC is one of the factors that can bind the MZF1 gene promoter (Suppl. Table 1). MYC 
appears to be regulated upstream and downstream of MZF1 suggesting a positive 
feedback loop. It may be significant that MZF1 target CDC37 can synergize with MYC in 
prostate carcinogenesis in transgenic mouse models(Stepanova, Finegold et al. 2000, 
Sironen, Karjalainen et al. 2002).  
 
Thus changes in expression, mutation and regulation of the MZF1 gene have been 
implicated in a wide spectrum of cellular malignancies.  One common theme running 
through many of the studies was the finding of MZF1-dependent transcriptional changes 
associated with malignant cell migration and invasiveness. These effects of MZF1 could be 
mediated through repression of differentiation factors such as CD34 and c-myb or the 
trans-activation of genes encoding effector proteins such as AXL and cathepsin B.  
Interestingly, the effects of MZF-1 are dependent on cancer type and thus we speculate a 
specific genetic milieu influence activity of MZF1. Such interactions require further 
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elucidation as might be critical for understanding cancer development as well as design of 
new therapeutic strategies.  
As a whole, these effects of MZF1 appear to be mediated by complex transcriptional 
networks that require such factors as MYC, FOXM1 and NKX2-1. Consequently, elucidating 
the function and interactions of MZF1 within this network will require further analysis.  
 
(2) MZF1 as a member of the SCAN-Zinc Finger transcription factor family 
 
 MZF1 belongs to the SCAN-ZF domain-pair gene cluster and is a component of the larger 
ZF, 600-member transcription factor family expressed only in vertebrates. The human 
genome has been shown to contain nearly seventy SCAN-ZF factors, including MZF1 itself 
(Edelstein and Collins 2005). SCAN-ZF family members possess a varied number of 
Cys2His2 zinc finger motifs that bind distinct DNA motifs, giving sequence specific 
recognition of target genes. In addition a small number of SCAN domain-only (SCAND) 
factors have been discovered that lack the DNA binding ZF domains and are currently 
thought to function as regulators of the intact SCAN-ZF factors that may be significant in 
cancer(Sander, Stringer et al. 2003, Edelstein and Collins 2005). As a promoter 
/enhancer-binding-type transcription factor, MZF1 functions as both a trans activator and 
trans-repressor, suggesting that its relative oncogenic activity may be an aggregate of 
increases and decreases in gene expression(Edelstein and Collins 2005).  
The MZF1 activating and repressing kinase phosphorylation signals, inter-molecular 
interactions are transcriptional gene targets are described herein, organized in Table 1 and 
modeled in Figure 2.    
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(3) The MZF1 gene 
 
Understanding the organization of the MZF1 gene and its regulation may give us a 
window through which to observe its involvement in malignancy. The human MZF1 gene 
(NCBI Gene ID: 7593) is located on the end of chromosome 19q with its 5’ end and 
promoter oriented towards the telomere, suggesting that telomere shortening in aging 
cells could affect MZF1 biology.  MZF1 encodes two unique isoforms produced by 
alternative splicing. A third isoform record of alternative transcription initiation was 
recently found to be an artifact and deleted from NCBI, however the isoform was 
maintained in the mouse record, thus suggesting a difference in species.  The ability of the 
MZF1 gene to encode multiple transcripts, likely with differing properties may play a 
significant role in its complex influences on tumorigenesis, as will be discussed below. 
The larger MZF1 isoform 1 (NM_03422.2) encodes a longer protein known as both MZF1A 
and MZF1B producing a 734 aa protein product (NP_003413.2). This factor contains the 
N-terminal SCAN domain followed by a regulatory linker connected to a C-terminal DNA 
binding domain containing 13 C2H2-type zinc finger (ZF) motifs.  Studies in murine MZF1 
place the trans-activation domain (TAD) within this linker region(Murai, Murakami et al. 
1997). A shorter MZF1 isoform 2 (NM_01267033.1) encodes a 290 aa protein product 
(NP_001253962.1) comprising of the SCAN domain, part of the regulatory linker and a 
unique C-terminal motif.  Interestingly this unique C-terminal motif lacks the 
phosphorylation sites predicted to reside in the corresponding region on MZF isoform 1 
as well as the C-terminal ZF DNA binding domains, suggesting unique functions for both 
MZF1 isoform 2 and the phosphorylation of MZF isoform 1 (Figure 2) (Peterson and 
Morris 2000).   
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The full repertoire of mechanisms of regulation of MZF1 gene expression have yet to be 
rigorously characterized. However global analysis of the human genome and proteome 
could provide some insights into the biology of MZF1.   Comprehensive ChIP-Seq profiling 
of 161 transcription factors indicated that the MZF1 gene promoter contained a single 
RNA polymerase 2 (POLR2A) binding site spanning the transcriptional start site (Hudson 
and Snyder 2006) (Euskirchen, Rozowsky et al. 2007) .  Within this POLR2A footprint 85 
different transcription factors were shown to map to 111 binding sites, with 24 such 
factors binding to more than one site (Suppl Table 1).  Notable transcription factors 
included MYC, HSF1, TRIM28, STAT3, RELA, MAX and ZNF143.  The observation that MYC 
bound to the MZF1 gene promoter may be of significance in regulating expression of the 
MZF1 gene in cancer (as discussed below).  Protein profiling of normal human tissue 
indicated that the MZF1 protein was most highly expressed in the thyroid and brain 
(Uhlen, Fagerberg et al. 2015) (Uhlen, Bjorling et al. 2005) (www.proteinatlas.org). 
  
(4) Regulation of MZF1 Function 
 
The intracellular mechanisms of MZF1 regulation are largely uncharacterized but 
examination of the available data suggested a number of levels of regulation including 
posttranslational modifications, dynamic intra-nuclear localization, protein-protein 
association and binding to transcriptional co-factors. 
 
(5) MZF1 and promyelocytic leukemia nuclear bodies (PML-NBs) 
 
 10 
MZF1 has been shown to concentrate in PML-NBs (Bernardi and Pandolfi 2007, Heun 
2007, Noll, Peterson et al. 2008).  PML-NBs are nuclear structures ranging in size from 
0.2-1.0 microns formed by the oligomerization of PML proteins along with, potentially 
over 160 other protein components(Van Damme, Laukens et al. 2010).  PML-NBs have 
been reported to critically influence transcriptional activity and chromosomal structure 
through interaction with such other factors(Dellaire and Bazett-Jones 2004) However, it 
is still not clear how residence in PML-NB regulates the transcriptional activity of factors 
such as PML and, potentially MZF1. 
 
MZF1 Regulation by SUMO modification   
MZF1 was shown to co-associate with PML-NB protein PML, a member of the tripartate 
motif family and the principle coordinator of PML-NB assembly, within the nuclear bodies 
through its N-terminal region as determined using immunofluorescence analysis(Jensen, 
Shiels et al. 2001, Noll, Peterson et al. 2008).  This region of MZF1 includes the SCAN 
domain, through which MZF1 also recruits other factors such as ZNF24 to PML-NBs(Noll, 
Peterson et al. 2008).  Entry into PML-NBs appear to require the post-translational 
modification by SUMO (small ubiquitin-related modifier) (Heun 2007, Raman, Nayak et al. 
2013).  SUMO modification (SUMOylation) has recently attracted considerable interest 
with regard to a role in cancer. Three SUMO paralogs exist in mammalian cells (SUMO1, 
SUMO2, SUMO3) that can be coupled to lysine residues in target proteins by a conjugation 
system analogous the one employed in protein ubiquitinylation, with E3 ligases such as 
Pias1 catalyzing the final coupling step (Bettermann, Benesch et al. 2012). The converse 
process, deSUMOylation is carried out by cysteine-protease-Sentrin-specific-proteases 
(SENP) (Bettermann, Benesch et al. 2012). As SUMOylation often inhibits the activity of 
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transcription factors, this process has been considered as a likely tumor suppressing 
function (Bettermann, Benesch et al. 2012). SENP molecules have thus been considered 
targets in cancer therapy: for instance, SENP1 is expressed to high level in human 
prostate cancer (Cheng, Bawa et al. 2006). However the role of these competing processes 
of SUMOylation and deSUMOylation in cancer appears to be complex and it has for 
instance been shown recently that modification of proteins including PML and 
TRIM28/Kap1 by SUMO2 and SUMO3 was increased in metastatic breast cancer 
(Subramonian, Raghunayakula et al. 2014). Remarkably in these studies, the increase in 
SUMOylated PML was accompanied by increased numbers of PML-NBs. It should be noted 
however that there are many isoforms of PML and these may have different functional 
consequences in cancer (Jensen, Shiels et al. 2001). 
SUMOylation of transcription factors has been often associated with gene repression 
(Stielow, Kruger et al. 2010, Raman, Nayak et al. 2013). The SUMO modification allows 
recognition by SUMO interacting motifs (SIM) in associated proteins (Raman, Nayak et al. 
2013). Inhibition of gene transcription after SUMOylation was shown to be due to 
recruitment of repressor proteins with SIM motifs, including Mi-2 containing complexes, 
SETDB1 and an LSD1-CoREST-HDAC1 complex (Stielow, Kruger et al. 2010, Tanaka and 
Saitoh 2010). SIM domains were found in each of the repressors. In addition SUMO/SIM 
interactions are critically involved in recruiting transcription factors to PML bodies (Noll, 
Peterson et al. 2008). Indeed PML itself contains a functional SIM and is modified by 
SUMOylation and these domains are involved in its role as a scaffold protein coordinating 
the assembly of PML-NBs (Cappadocia, Mascle et al. 2015). Recruitment of the repressor 
DAXX to the PML-NBs also requires a SIM domain (Chang, Naik et al. 2011).  
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Noll et al suggested that SUMOylation occurred within amino acids 37-128 of MZF1 (Noll, 
Peterson et al. 2008). Notably, this sequence contains only one lysine residue at K81. The 
site of the SUMO recognition site was not ascertained by this group although Noll et al 
suggested a sequence in the N-terminus-(aa 15-28) (Noll, Peterson et al. 2008). In 
addition, this region contains a consensus SIM site in the N terminus with a motif 
containing 4 adjacent hydrophobic amino acids- (hydrophobic amino acids at aa 86-90 
(LLVL) (Figure 4). This site is embedded within a region of negative charge with a serine 
residue at aa79- again found in many SIMs. Recent studies by Cappadocia et al have 
shown phosphorylation within the SIM domains of PML and DAXX strongly enhances 
interactions with SUMO (Cappadocia, Mascle et al. 2015).  
There is strong evidence to indicate that PML-NB may be involved in gene repression and 
indeed have been also associated with tumor suppression (Jensen, Shiels et al. 2001): In 
addition, the loss of PML-NBs was shown to play a key role in development of acute 
promyelocytic leukemia(Jensen, Shiels et al. 2001). The studies of Pandolfi et al showed 
that knockout of the MZF1 gene led to development of cancer strongly suggesting a 
potential cancer suppressive activity by MZF1 in this disease(Gaboli, Kotsi et al. 2001). 
MZF1 SUMOylation might thus play a key role in transcriptional function and it is 
tempting to speculate that the SUMOylated form may play key roles in gene repression, as 
with PML. 
 
 
 
(6) Upstream activation of MZF1 by phosphorylation and SUMOylation. 
 
 13 
In accordance with the phospho-SIM studies of PML one might speculate that S79 of MZF1 
could be phosphorylated when MZF1 enter the PML-NBs. S79 is in a region rich in 
negative charge and could thus be a potential substrate for CK2 that modifies S or T 
residues within regions of negatively charged amino acids (as is seen with PML). As 
mentioned above, MZF1 can be activated downstream of TGF-receptor II-activated Erb-
B2 in breast cancer through a signaling pathway involving the ERK2 kinase, although the 
phosphorylation site on MZF1 was not characterized (Rafn, Nielsen et al. 2012). Screening 
by mass spectrometry has identified 7 phosphorylated residues in MZF1, including at 
T169, S177, T210, S256, S274, S294 and S347 in the linker domain /TAD (trans activation 
domain), S111 in the SCAN domain and T592 in the ZF domain 
(http://www.phosphosite.org) (Fig. 21). In addition a screen for CDK4 and CDK6 
phosphorylation indicates MZF1 as a confirmed candidate for modification by both 
kinases (Anders, Ke et al. 2011). S256, S274 and S294 each resemble consensus cyclin 
dependent kinase sites on the basis of amino acid sequence and S274 could potentially be 
a substrate for the kinase ERK2. However, at this time, none of these phosphorylation 
sites have been characterized as activating or suppressing MZF1 in focused biology 
studies, although they might suggest a key regulatory role for the linker / TAD region. 
Studies on the murine Mzf1 aka Mzf2/Zfp121/Zfp98/Znf42 (NCBI Reference Sequence: 
NP_665818.2) encoded by the murine mzf1 gene (NCBI gene ID: 109889), that shares 
considerable homology with homo sapiens MZF1, similarly containing 13 ZF motifs 
indicated multiple phosphorylation by MAP kinase family members such as ERK (Ogawa, 
Murayama et al. 2003). Phosphorylation took place in the Linker / TAD domain and led to 
inhibition of MZF1-mediated transcription. It is not clear to what degree these results can 
be extrapolated to human MZF1 although the considerable sequence similarity might 
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suggest this possibility (Murai, Murakami et al. 1997). These phosphorylation sites in 
murine Mzf1  (S257, 275, 295) occur on similar residues to those found in human MZF1 
isoform 1 at S256, 274, 294 (as mentioned above), suggesting possible functional 
significance for these sites in human MZF1. There are many evidence of phosphorylation-
directed SUMO modification (PDSM) with in the consensus PDSM sequence KxExxSP 
(Figure 4); however, phosphorylation does not inevitably enhance sumoylation of 
adjacent residues. For instance in the protein TRIM28/Kap1, a factor that associates with 
Kruppel family ZF proteins, phosphorylation on serine 824 by PIKK family kinases led to 
loss of Sumo from the N-terminus, inhibition of gene repressive activity and gain of trans-
activating function(Bunch, Zheng et al. 2014) (Iyengar and Farnham 2011). Interestingly, 
both TRIM28 and PML belong to the tripartate motif family of factors and TRIM28 has 
been found to accumulate in Kap1 bodies, structures that have marked similarity to PML-
NBs. (Briers, Crawford et al. 2009) 
 
(7) Regulation of MZF1 by protein-protein interactions 
 
As mentioned above, the SCAN box is a key protein interaction domain allowing SCAN-ZF 
proteins such as MZF1 to form dimers (Edelstein and Collins 2005). These interactions 
include formation of both MZF1 homodimers and heterodimers with other SCAN box-
containing proteins (Sander, Stringer et al. 2003, Edelstein and Collins 2005, Noll, 
Peterson et al. 2008). The importance of dimerization for SCAN-ZF transcriptional activity 
was shown in studies on ZNF174 using GAL4 VP16 two hybrid experimental system. In 
these studies a ZNF SCAN-VP16 trans-activating fusion construct and a ZNF174 SCAN-
GAL4 DNA binding fusion construct were shown to co-activate transcription from a GAL4 
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binding sites containing reporter construct, indicating that SCAN domain interacts / 
dimerizes with another SCAN domain in this system and synergistically activates 
transcription (Williams, Blacklow et al. 1999).  
The presence of a highly conserved SCAN box in the SCAN-ZF family also suggested that a 
network of interactions between family members may occur through heterodimerization 
(Edelstein and Collins 2005). MZF1 for instance has been shown to interact with family 
members ZNF24, ZNF174 and ZNF202 in SCAN-SCAN box interactions (Noll, Peterson et 
al. 2008). Indeed family member ZNF24 was shown to accompany MZF1 into PML-NBs in 
a SCAN box dependent localization manner (Noll, Peterson et al. 2008). However, 
although the SCAN box is highly conserved, not all SCAN domains are able to form dimers 
indicating some limit to potential partnering between SCAN-ZF members (Edelstein and 
Collins 2005). 
MZF1 can also interact with a SCAN box-containing protein deficient in ZF domains 
known as RAZ1 (SCAN-related protein associated with MZF1) or SCAND1 /RAZ108, which 
are also shown as SCAND1 variant 1 and variant 2 (Sander, Haas et al. 2000). The exact 
significance of this interaction is not clear although “zinc fingerless” SCAND1 might 
attenuate MZF1 signaling through diminished affinity for DNA targets or other 
interactions (Sander, Haas et al. 2000). Indeed ZF domains can interact with proteins as 
well as DNA (Edelstein and Collins 2005). 
Transactivation by MZF1 would likely involve the recruitment of co-activating molecules 
although little information is available in this regard. However study of the murine Mzf1 
paralog indicated its interaction with the SWI/SNF2-type DNA remodeling protein 
mDomino (Ogawa, Ueda et al. 2003). mDomino was shown to bind the TAD  of Mzf1  and 
activated transcription of a reporter construct (Ogawa, Ueda et al. 2003). In addition 
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human MZF1 was shown to bind to LDOC1, a protein whose expression is reduced in 
pancreatic and gastric cancer. LDOC1 was shown to encode a leucine zipper domain and 
SH3 like proline rich domain and this association led to enhancement of apoptosis in 
Jurkat and K562 cells (Inoue, Takahashi et al. 2005). 
MZF1 has also been associated with trans-repression of some genes. Takahashi et al 
showed that MZF1 could bind the co-repressor FHL3 (four and a half Lim domain protein-
3) that interacts with cancer development regulators Smad 2, 3 and 4 (Takahashi, 
Matsumoto et al. 2005).  Human Fc epsilon RI beta-chain expression was repressed by 
MZF1, through an element in the fourth intron and transcriptional repression by MZF1 
required FHL3 as a cofactor (Takahashi, Matsumoto et al. 2005). Gene repression by 
factors such as PML and DAXX has been strongly associated with residence in PML-NBs 
suggesting the possibility that MZF1 found in such locations might be repressive to target 
genes.  
 
(8) Conclusions 
 
There is a growing evidence of a role for MZF1 in cancer and certainly its 
posttranslational modification will influence its role as a gene repressor or activator. 
Although the initial studies of MZF1 in malignant progression concentrated on its role in 
promyelocytic leukemia, the factor now appears to be involved in the etiology of a 
number of major solid tumor types, such as lung, cervical, breast and colorectal cancer  
(Tsai, Hwang et al. 2012) (Mudduluru, Vajkoczy et al. 2010, Rafn, Nielsen et al. 2012, Tsai, 
Wu et al. 2014). These properties may at least partially reflect increases in MZF1 gene 
copy number and rate of mutation in many cancers (Fig. 1).  
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A theme common to many of the studies reviewed here was the finding of MZF1-
dependent transcriptional changes in malignant cell migration and 
invasiveness(Reymann and Borlak 2008, Mudduluru, Vajkoczy et al. 2010, Rafn, Nielsen et 
al. 2012). These effects of MZF1 at least in promyelocytic leukemia could be mediated 
through repression of differentiation factors such as CD34 and c-myb or the trans-
activation of genes encoding effector proteins such as AXL and cathepsin B(Perrotti, 
Melotti et al. 1995, Mudduluru, Vajkoczy et al. 2010, Rafn, Nielsen et al. 2012). It is 
interesting to note that a number of studies place MZF1 downstream of TGF-, a factor 
known to be important in invasion, migration and the EMT phenotype (Massague 2008). 
MZF1 activation by TGF-, may involve one or more of the phosphorylation sites 
characterized in MZF1(Driver, Weber et al. 2015) (Fig. 3). 
Although much information has accrued regarding mechanisms of transcriptional 
regulation by MZF1, major questions remain unanswered. These include the nature of 
PTMs that regulate function and their coupling to upstream signaling. MZF1 is modified 
by phosphorylation and SUMOylation as mentioned above, although the significance of 
these processes is still emerging. Phosphorylation of MZF1 appears to be required for 
responses to the activating effects of TGF- stimulation (Rafn, Nielsen et al. 2012, Driver, 
Weber et al. 2015). Likewise the role of SUMOylation and entry of MZF1 into PML-NBs 
may play a significant role in regulation of gene expression in  the malignant cell(Noll, 
Peterson et al. 2008). Indeed the SUMOylation sites and SUMO-interaction motifs (SIMs) 
are predicted in human and mouse MZF1 (Fig. 4). SUMOylation of transcription factors is 
usually associated with the recruitment of co-repressors, and this process may thus 
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mediate some of the repressive processes orchestrated  by MZF1 in differentiation and 
cancer (Stielow, Kruger et al. 2010, Tanaka and Saitoh 2010).   
Other questions related to MZF1 and its role in cancers that may require study include:  
(1) the nature of associated transcription factors including dimerization partners 
containing the SCAN domain and their role in trans activation. SCAN domain partners may 
either synergize with MZF1 or, in the case of the zinc fingerless protein SCAND1 may 
inhibit the factor. This may be a highly significant mode of inhibition as SCAND1 levels are 
high in normal prostate and may inhibit unscheduled MZF1 activity (GeneAtlas U133A 
gcrma). In addition MZF1 may interact with transcription factors from other families 
outside the SCAN-ZF cluster. Of particular significance is MYC, a protein that may function 
both upstream and downstream of MZF1(Tsai, Wu et al. 2014) (Suppl. Table 1).(2) 
Recruitment of co-activators and co-repressors by MZF1. Murine Mzf1 is known to 
interact with the chromatin remodeling factor mDomino, a protein that can function to 
insert the non-canonical histone H2AZ into chromatin(Ogawa, Ueda et al. 2003, Fujii, 
Ueda et al. 2010) Elevated levels of H2AZ are associated with rapid transcription (Redon, 
Pilch et al. 2002). Sumoylated MZF1 might be expected to interact with the SIM domains 
of gene repressors as described above, although this connection has not been formally 
proven. Future studies will address cell signaling in cancer and association of activators 
and repressors with MZF1. (3) Global interactions of MZF1 with the human genome. 
Determining the global interactions of MZF1 with the genomes of normal and malignant 
cells is clearly an important next step in the project of assessing the importance of this 
factor and its transcriptional targets in cancer. 
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Answers to these questions may permit us to consider strategies to targeting this 
intriguing factor in cancer or assessing MZF1 as a biomarker for cancer diagnosis and 
prognosis. 
 
Legends 
 
Figure 1. Frequency of MZF1 alterations across tumor types profiled by The Cancer 
Genome Atlas (TCGA).   
Samples of each tumor type or cell line collection, listed along the x-axis, were analyzed 
for MZF1 gene copy number alterations (CNA) and open reading frame mutations.  The 
percentage of alterations for each sample set is listed along the y-axis. The NCI-60 cancer 
cell line collection shows the largest percentage of alterations at 13.2% (7 out of 53 cases) 
for MZF1.  This is followed by Breast Cancer Xenografts at 10.3% (3 out of 29 cases), 
Colorectal Adenocarcinoma at 8.3% (6 mutations out of 72 cases), Cancer Cell Line 
Encyclopedia at 6.5% (30 amplifications, 27 deletions out of 881cases) and Bladder 
Cancer at 5.5% (7 out of 127 cases). All other tumor types are listed in descending order 
of percentage of MZF1 alteration.  Interestingly MZF1 was deleted in 4.2% (12 out of 286 
cases) of Brain Low Grade Gliomas analyzed.  All samples were processed as a part of the 
U.S. national TCGA initiative to quantitatively characterize over 80 forms of cancer at the 
molecular level.  Information was gathered and graphed by the cBioPortal site (Cerami, 
Gao et al. 2012, Gao, Aksoy et al. 2013).  
 
Figure 2. The domain structure, post-translational modifications (PTMs) and 
expressed isoforms of MZF1. human MZF1 (isoform 1) consists of N-terminal SCAN box, 
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linker region and C-terminal 13 Zinc finger (ZF) motifs. SCAN box functions in  
dimerization or oligmerization of SCAN-ZF proteins. The linker region contains serine 
residues, which can be phosphorylated by kinases, and is an Asparate and Glutamate-rich 
acidic region, so that this linker region is functionally called regulatory domain. This 
region also appears to contain the TAD domain. ZF domain the DNA binding region (DBD). 
A glycine and proline-rich linker region at (463-484), could mediate bending, flexibility 
and inter-molecular interactions of this protein. Phosphorylation sites were referred by 
Phosphositeplus. Two phospho-directed SUMO sites at K23/S27 and K184/S187 were 
predicted using SUMOplot and GPS-SUMO at high scores (see later figure). MZF1 isoform 
2, which is generated by alternative splicing, consists of the SCAN box and the regulatory 
domain, in which amino acids 259-290 including serine 274 were replaced (serines were 
shown in red). MZF1 isoform 3 consists of the regulatory region and ZF motifs (9 ZFs). 
This 3rd isoform was validated in mouse in the NCBI protein database, but recently 
deleted in human. Validated MZF1 isoform 2 in mouse is 542 aa, while human MZF1 
isoform 2 is 290 aa. Natural variants and a sequence conflicts were mapped. 
 
Figure 3.  A model for regulation and roles of MZF1 in cancer. LKB1 phosphorylates 
MZF1 for transcriptional repression of CD34 and MYB genes, which are inhibiting cancer 
cell migration and invasion(Perrotti, Melotti et al. 1995). In contrast, a battery of kinases 
was recently reported to be involved in MZF1 transcriptional activation of AXL and CTSB, 
both of which promote migration and invasion of cancer cells (Peterson and Morris 2000, 
Rafn, Nielsen et al. 2012). MZF1 can form homo- or hetero- dimers or oligomers with 
other SCAN-ZF or SCAN box proteins(Peterson and Morris 2000). MZF1 undergoes post-
translational modifications (PTMs) including phosphorylation, sumoylation and 
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presumably acetylation and ubiquitinylation(Noll, Peterson et al. 2008). 
SUMO1modification of MZF1 enables interaction with SUMO-interaction motif (SIM)-
containing proteins such as PML(Noll, Peterson et al. 2008). Enzymes, transcription 
factors and other molecules stored in PML-NBs could potentially further give rise to 
further PTMs in MZF1 and modulate its function in gene regulation.  
 
Figure 4. Prediction of sumoylation and SUMO-interaction motifs (SIM) in MZF1.  
(For references see(Bettermann, Benesch et al. 2012, Raman, Nayak et al. 2013, 
Cappadocia, Mascle et al. 2015))(A) Sumoylation motifs in MZF1: PDSM, phospho-
directed SUMO modification. NDSM, negatively charged amino acid dependent SUMO 
modification. SUMO-2/3 targets inverted motifs and hydrophobic cluster motifs. (B) 
different types of SIMs. Serine can be negatively charged upon phosphorylation. Ac, acidic 
amino acids. (C) Sumoylation site prediction in MZF1. Sites were predicted in SUMOplot 
(P) and GPS-SUMO (G) shown in scores. K and E are boxed. human MZF1 isoform 1 and 
mouse MZF1 isoform 1 (NP_665818.2)were input and aligned. (D) SIM prediction in 
MZF1. SIMs are predicted in GPS-SUMO setting a low threshold as cut off score = 55.31. 
Note that MZF1 aa 13-30 PPEDEGPVMVKLEDSEEE contains both a potential sumoylation 
site and a predicted SIM. 
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Figure	  3	  
ψKxE	   	   	  Consensus	  moMf	  
ExKψ 	   	  Inverted	  moMf	  	  (SUMO-­‐2/3)	  
ψψψψKxE 	  Hydrophobic	  cluster	  moMf	  	  (SUMO-­‐2/3)	  
ψKxExxSP 	  PDSM	  	  
ψKxExxAcAcAc	  	   	  NDSM	  	  
	  
ψψxψAcAcAcAcAc	   	  SIMa	  
ψψDLT	   	   	   	  SIMb	  
AcAcAcAcAcψxψψ	   	  SIMr	  (reversed)	  
	  
   ψ	  =	  V,	  I	  or	  L	  (hydrophobic	  aa)	  
	  	  	  Ac	  =	  D,	  E	  or	  pS	  (negaMvely	  charged	  aa)	  
A	  	  (sumoyla+on	  mo+fs)	   B	  (SIMs)	  
SUMOplot 	  hYp://www.abgent.com/sumoplot	  
GPS-­‐SUMO 	  hYp://sumosp.biocuckoo.org/	  
PCI-­‐SUMO 	  hYp://bioinf.sce.carleton.ca/SUMO/start.php	  
	  
E	  (SUMO	  predicMon	  tools)	  
C	  (sumoyla+on	  site	  predic+on	  in	  MZF1)	  
species  position          alignment   score(P) score(G)
h   K23 EGPVM VKLE DSEEE  0.93 58.988
m   K22 NEPAL VKLE DSDSD  0.93
h   K184 PLGLQ VKEE SEVTE  0.93 44.651
m   K185 PLNLP MKEE TELLG  0.8
h   K146 QEVLS EKME PSSFQ  0.5 19.314
m   K147 KEVLS EKME PSSFQ  0.5
D	  (SIM	  predic+on	  in	  MZF1)	  
Position      Peptide     Score
20-24 PPEDEGP VMVKL EDSEEEG  58.988
222-226 EAQRCGT VLDQI FPHSKTG  57.35
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